Lexeo Therapeutics

Update in progress

LXEO (NasdaqGM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Lexeo Therapeutics is a clinical-stage genetic medicine company focused on hereditary and acquired cardiac diseases with high unmet need in the United States. Its pipeline includes LX2006 (phase 1/2) for Friedreich ataxia–related cardiomyopathy; LX2020 (phase 1/2) delivering PKP2 to cardiac muscle for PKP2-ACM; LX2021 (preclinical) delivering Cx43 for ACM and related DCM; LX2022 (preclinical) delivering TNNI3 for hypertrophic cardiomyopathy. It also pursued APOE4 Alzheimer’s programs LX1001, LX1020, LX1021. Founded 2017, based in New York.

Company score

Sentiment: 0.20; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.05; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.03; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.02; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.11; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive